I’m Brenna Kelley-Clarke, Ph.D., a virologist and viral vector development leader with more than 15 years of experience in gene and cell therapy. I earned my doctorate at Harvard University and have led scientific teams in industry, most recently as Senior Director and Head of Vector Attribute Sciences at Bristol Myers Squibb.

At Bristol Myers Squibb, I led teams responsible for viral vector analytics, formulations, and process development. My work spanned AAV and lentiviral vector programs and included supporting manufacturing scale-up, analytical strategy, and cross-functional decision-making across development programs.

I founded Brenna Consulting to bring my experience in viral vector development, CMC, and analytics to organizations working to advance gene and cell therapy programs. My work has spanned early development through late-stage programs and regulatory submission, with a focus on translating complex technical questions into practical development decisions.